



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations

Citation for published version:

SUNLIGHT consortium & The GEFOS consortium 2013, 'Meta-analysis of genome-wide association studies identifies six new Loci for serum calcium concentrations', *PLoS Genetics*, vol. 9, no. 9, e1003796.
<https://doi.org/10.1371/journal.pgen.1003796>

Digital Object Identifier (DOI):

[10.1371/journal.pgen.1003796](https://doi.org/10.1371/journal.pgen.1003796)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

PLoS Genetics

Publisher Rights Statement:

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Meta-Analysis of Genome-Wide Association Studies Identifies Six New Loci for Serum Calcium Concentrations

Conall M. O'Seaghdha^{1,2†}, Hongsheng Wu^{1,3,4}, Qiong Yang^{1,3}, Karen Kapur⁵, Idris Guessous^{6,7,8†}, Annie Mercier Zuber⁹, Anna Köttgen^{10,11†}, Candice Stoudmann⁹, Alexander Teumer¹², Zoltán Kutalik^{5,13}, Massimo Mangino¹⁴, Abbas Dehghan¹⁵, Weihua Zhang^{16,17}, Gudny Eiriksdottir¹⁸, Guo Li¹⁹, Toshiko Tanaka²⁰, Laura Portas²¹, Lorna M. Lopez²², Caroline Hayward²³, Kurt Lohman²⁴, Koichi Matsuda²⁵, Sandosh Padmanabhan²⁶, Dmitri Firsov⁹, Rossella Sorice²⁷, Sheila Ulivi²⁸, A. Catharina Brockhaus^{29,30}, Marcus E. Kleber^{31,32}, Anubha Mahajan³³, Florian D. Ernst¹², Vilmundur Gudnason^{18,34}, Lenore J. Launer³⁵, Aurelien Mace^{5,13}, Eric Boerwinckle³⁶, Dan E. Arking³⁷, Chizu Tanikawa²⁵, Yusuke Nakamura²⁵, Morris J. Brown³⁸, Jean-Michel Gaspoz³⁹, Jean-Marc Theler⁷, David S. Siscovick^{19,40}, Bruce M. Psaty^{19,41,42}, Sven Bergmann^{5,13}, Peter Vollenweider⁴³, Veronique Vitart²³, Alan F. Wright²³, Tatijana Zemunik⁴⁴, Mladen Boban⁴⁵, Ivana Kolcic⁴⁴, Pau Navarro²³, Edward M. Brown⁴⁶, Karol Estrada⁴⁷, Jingzhong Ding⁴⁶, Tamara B. Harris³⁵, Stefania Bandinelli⁴⁸, Dena Hernandez⁴⁹, Andrew B. Singleton⁴⁹, Giorgia Grotto²⁸, Daniela Ruggiero²⁷, Adamo Pio d'Adamo²⁸, Antonietta Robino²⁸, Thomas Meitinger^{50,51}, Christa Meisinger⁵², Gail Davies²², John M. Starr²², John C. Chambers^{16,17,53}, Bernhard O. Boehm^{54,55}, Bernhard R. Winkelmann⁵⁶, Jie Huang⁵⁷, Federico Murgia²¹, Sarah H. Wild⁵⁸, Harry Campbell⁵⁸, Andrew P. Morris³³, Oscar H. Franco¹⁵, Albert Hofman¹⁵, Andre G. Uitterlinden⁴⁷, Fernando Rivadeneira⁴⁷, Uwe Völker¹², Anke Hannemann⁵⁹, Reiner Biffar⁶⁰, Wolfgang Hoffmann⁶¹, So-Youn Shin⁶², Pierre Lescuyer⁶³, Hughes Henry⁶⁴, Claudia Schurmann¹², The SUNLIGHT consortium, The GEFOS consortium, Patricia B. Munroe⁶⁵, Paolo Gasparini²⁸, Nicola Pirastu²⁸, Marina Ciullo²⁷, Christian Gieger²⁹, Winfried März^{32,66}, Lars Lind⁶⁷, Tim D. Spector¹⁴, Albert V. Smith^{18,34}, Igor Rudan⁵⁸, James F. Wilson⁵⁸, Ozren Polasek⁴⁴, Ian J. Deary²², Mario Pirastu²¹, Luigi Ferrucci³⁵, Yongmei Liu⁶⁸, Bryan Kestenbaum⁶⁹, Jaspal S. Kooner^{16,70,71}, Jacqueline C. M. Witteman¹⁵, Matthias Nauck⁵⁹, W. H. Linda Kao^{11,72}, Henri Wallaschofski^{59†}, Olivier Bonny^{9,73,74†}, Caroline S. Fox^{1,74,75†}*, Murielle Bochud^{69†}*

1 National Heart, Lung, and Blood Institute's Framingham Heart Study and Center for Population Studies, Framingham, Massachusetts, United States of America, **2** Renal Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **3** Department of Biostatistics, Boston University, Boston, Massachusetts, United States of America, **4** Department of Medical Biology, University of Split, School of Medicine, Split, Croatia, **5** Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland, **6** Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland, **7** Unit of Population Epidemiology, Division of Primary Care Medicine, Department of Community Medicine and Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland, **8** Geriatric Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy, **9** Department of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland, **10** Renal Division, Freiburg University Hospital, Freiburg, Germany, **11** Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, **12** Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany, **13** Swiss Institute of Bioinformatics, Lausanne, Switzerland, **14** King's College London, St. Thomas' Hospital Campus, London, United Kingdom, **15** Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands, **16** Catheter Lab, Cardiology, Ealing Hospital, Southall, Middlesex, United Kingdom, **17** Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom, **18** Icelandic Heart Association Research Institute, Kopavogur, Iceland, **19** Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, United States of America, **20** Clinical Research Branch, National Institute on Aging, Baltimore, Maryland, United States of America, **21** Institute of Population Genetics, CNR-Traversa La Crucca, Reg. Balduina Li Punti, Sassari, Italy, **22** Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, Edinburgh, United Kingdom, **23** MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom, **24** Cardiology Group, ClinPhenomics GmbH&Co KG, Frankfurt-Sachsenhausen, Germany, **25** Laboratory of Molecular Medicine and Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, **26** BHF Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, **27** Institute of Genetics and Biophysics 'Adriano-Buzzati Traverso', CNR, Napoli, Italy, **28** Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy, **29** Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany, **30** Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians University Munich, Munich, Germany, **31** Department of Internal Medicine II – Cardiology, University of Ulm Medical Centre, Ulm, Germany, **32** Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, **33** Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, United Kingdom, **34** University of Iceland, Reykjavik, Iceland, **35** Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, Bethesda, Maryland, United States of America, **36** University of Texas Health Science Center at Houston, Houston, Texas, United States of America, **37** McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, **38** Cambridge Institute of Medical Research, University of Cambridge, Cambridge, United Kingdom, **39** Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, **40** Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, United States of America, **41** Group Health Research Institute, Group Health Cooperative, Seattle, Washington, United States of America, **42** Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington, United States of America, **43** Department of Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland, **44** Faculty of Medicine, University of Split, Split, Croatia, **45** Department of Pharmacology, Faculty of Medicine, University of Split, Split, Croatia, **46** Division of Laboratory Medicine, Geneva University

Hospitals, Geneva, Switzerland, **47** Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, **48** Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom, **49** Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, United States of America, **50** Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany, **51** Department of Computer Science and Networking, Wentworth Institute of Technology, Boston, Massachusetts, United States of America, **52** Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany, **53** Epidemiology and Biostatistics, Imperial College London, Norfolk Place, London, United Kingdom, **54** Ulm University Medical Centre, Department of Internal Medicine I, Ulm University, Ulm, Germany, **55** LKC School of Medicine, Imperial College London and Nanyang Technological University, Singapore, Singapore, **56** Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America, **57** Division of Primary Care Medicine, Department of Community Medicine and Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland, **58** Centre for Population Health Sciences, The University of Edinburgh Medical School, Edinburgh, Scotland, United Kingdom, **59** Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany, **60** Department of Prosthetic Dentistry, Gerostomatology and Dental Materials, University Medicine Greifswald, Greifswald, Germany, **61** Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, **62** Human Genetics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom, **63** Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, **64** Clinical Chemistry Laboratory, Lausanne University Hospital, Lausanne, Switzerland, **65** William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, **66** Synlab Centre of Laboratory Diagnostics, Heidelberg, Germany, **67** Institute of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden, **68** Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, **69** Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington, United States of America, **70** Faculty of Medicine, National Heart & Lung Institute, Cardiovascular Science, Hammersmith Hospital, Hammersmith Campus, Imperial College London, London, United Kingdom, **71** Imperial College Healthcare NHS Trust, London, United Kingdom, **72** Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland, United States of America, **73** Service of Nephrology, Lausanne University Hospital, Lausanne, Switzerland, **74** Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Calcium is vital to the normal functioning of multiple organ systems and its serum concentration is tightly regulated. Apart from *CASR*, the genes associated with serum calcium are largely unknown. We conducted a genome-wide association meta-analysis of 39,400 individuals from 17 population-based cohorts and investigated the 14 most strongly associated loci in $\leq 21,679$ additional individuals. Seven loci (six new regions) in association with serum calcium were identified and replicated. Rs1570669 near *CYP24A1* ($P = 9.1\text{E-}12$), rs10491003 upstream of *GATA3* ($P = 4.8\text{E-}09$) and rs7481584 in *CARS* ($P = 1.2\text{E-}10$) implicate regions involved in Mendelian calcemic disorders: Rs1550532 in *DGKD* ($P = 8.2\text{E-}11$), also associated with bone density, and rs7336933 near *DGKH/KIAA0564* ($P = 9.1\text{E-}10$) are near genes that encode distinct isoforms of diacylglycerol kinase. Rs780094 is in *GCKR*. We characterized the expression of these genes in gut, kidney, and bone, and demonstrate modulation of gene expression in bone in response to dietary calcium in mice. Our results shed new light on the genetics of calcium homeostasis.

Citation: O'Seaghdha CM, Wu H, Yang Q, Kapur K, Guessous I, et al. (2013) Meta-Analysis of Genome-Wide Association Studies Identifies Six New Loci for Serum Calcium Concentrations. *PLoS Genet* 9(9): e1003796. doi:10.1371/journal.pgen.1003796

Editor: Gonalo R. Abecasis, University of Michigan, United States of America

Received: February 8, 2013; **Accepted:** July 29, 2013; **Published:** September 19, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: All grant numbers for each human study and for the animal studies are listed in the Acknowledgement section of the Supplementary material. There is no specific funding for the GWAS meta-analysis itself. Grant numbers: N01-AG-1-2100, HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HSN268201100012C, R01HL087641, R01HL59367, R01HL086694, U01HG004402, HHSN268200625226C, KO3598/2-1, UL1RR025005, N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, HHSN268201200036C, HL080295, HL087652, HL105756, AG-023629, AG-15928, AG-20098, AG-027058, UL1RR033176, UL1TR000124, DK063491, 33CSCO-122661, 3200BO-111361/2, 3100AO-116323/1, 310000-112552, LSHG-CT-2006-018947, 108-1080315-0302, 108-1080315-0302, N01-HC-25195, N02-HL-6-4278, N01AG62101, N01AG62103, N01AG62106, 1R01AG032098-01A1, HHSN268200782096C, ICS110.1/RF97.71, 263 MD 9164 and 263 MD 821336, SP/04/002, G0700704/84698, (MIUR) no. 5571/DSPAR/2002 and (FIRB) D. M. no. 718/Ric/2005, LSHG-CT-2006-018947, 01ZZ9603, 01ZZ0103, 01ZZ0403, 03IS2061A, 03ZIK012, 175.010.2005.011, 911-03-012, 014-93-015, RIDE2, 050-060-810, vici, 918-76-619, Vasoplus-037254, FIRB - RBIN064YAT, LSHM-CT-2004-503485, WT064890, WT081682, 01ZZ9603, 01ZZ0103, and 01ZZ 0403, 03IS2061A, 03ZIK012, HEALTH-F2-2008-201865-GEFOS, HEALTH-F4-2007-201413, QLQ2-CT-2002-01254, G20234, 091746/Z/10/Z, G9521010D, PG/02/128, SP/04/002, SP/04/002, PP00P3-133648. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: foxca@nhlbi.nih.gov (CSF); Murielle.Bochud@chuv.ch (MB)

These authors contributed equally to this work.

Writing group.

Introduction

Normal calcium homeostasis is regulated by three major hormones acting on their corresponding receptors in gut, kidney, and bone: parathyroid hormone (PTH) release governed by the calcium-sensing receptor (CASR), calcitonin, and the active

metabolite of vitamin D, $1,25(\text{OH})_2\text{-D}$. Despite heritability estimates of 33–78%, the genetic determinants of serum calcium are poorly understood [1,2,3]. We have previously reported a variant in *CASR* associated with calcium concentrations in European-ancestry individuals [4,5]. To detect additional loci, we conducted a two-stage genome-wide association meta-analysis

Author Summary

Calcium is vital to many biological processes and its serum concentration is tightly regulated. Family studies have shown that serum calcium is under strong genetic control. Apart from *CASR*, the genes associated with serum calcium are largely unknown. We conducted a genome-wide association meta-analysis of 39,400 individuals from 17 population-based cohorts and investigated the 14 most strongly associated loci in $\leq 21,679$ additional individuals. We identified seven loci (six new regions) as being robustly associated with serum calcium. Three loci implicate regions involved in rare monogenic diseases including disturbances of serum calcium levels. Several of the newly identified loci harbor genes linked to the hormonal control of serum calcium. In mice experiments, we characterized the expression of these genes in gut, kidney, and bone, and explored the influence of dietary calcium intake on the expression of these genes in these organs. Our results shed new light on the genetics of calcium homeostasis and suggest a role for dietary calcium intake in bone-specific gene expression.

of serum calcium and studied expression of identified genes in key calcium homeostatic organs in the mouse under various calcium diets.

Results

Genome-wide association meta-analysis in Europeans

The discovery analysis consisted of 39,400 individuals from 17 population-based cohorts of European descent (**Table 1** and **Table S1**). There was little evidence for population stratification at study level (median genomic inflation factor, $\lambda = 1.006$) or meta-analysis level ($\lambda = 1.03$), and we detected an excess of association signals beyond those expected by chance (**Figure S1**).

The *CASR* locus, previously identified in Europeans, was confirmed in our meta-analysis ($P = 6.5\text{E-}59$, **Figure S2**) [4,5]. In addition, SNPs from five independent regions reached genome-wide significance ($P < 5\text{E-}08$) in the overall discovery meta-analysis (**Figure 1**, **Table 1**, **Table S2**): rs1550532 (in *DGKD*, $P = 4.60\text{E-}08$), rs780094 (in *GCKR*, $P = 3.69\text{E-}11$), rs17711722 (near *VKORC1L1*, $P = 2.78\text{E-}11$), rs7481584 (in *CARS*, $P = 9.21\text{E-}10$) and rs1570669 (near *CYP24A1*; $P = 3.98\text{E-}08$).

Fourteen SNPs from Stage 1 were sent for Stage 2 validation in $\leq 21,679$ additional Europeans: the twelve independent (≥ 1 Mb apart) SNPs with lowest P values ($6.5\text{E-}59$ to $8.1\text{E-}06$) in Europeans and two additional genome-wide significant loci (rs9447004 and rs10491003) from a combined sample including 8318 Indian-Asians (**Table 1**). Of the fourteen SNPs, seven were considered successfully replicated (i.e. were in the same direction of effect as the discovery meta-analysis, had a one-side replication $P < 0.05$ and were genome-wide significant ($P < 5\text{E-}8$) in combined meta-analysis of discovery and replication sets). These were rs1801725 in *CASR*, rs1550532 in *DGKD*, rs780094 in *GCKR*, rs7336933 near *KLAA0564* and *DGKH*, rs10491003 (closest gene *GATA3*), rs7481584 in *CARS* and rs1570669 near *CYP24A1* (**Table 1**). Regional association plots are presented in **Figure S3**. Details on the seven SNPs that did not replicate are presented in **Table S2**. Association results for serum calcium in Caucasians for all SNPs with P value $< 5\text{E-}5$ are listed in **Table S3**. In a secondary analysis, all SNPs identified in the primary analysis showed consistent and significant association with serum calcium adjusted for serum albumin (**Table S4**, **Figure S4**), as well as an

excess of association signals beyond those expected by chance (**Figure S5**); no additional locus was identified using albumin-corrected serum calcium (**Table S5**).

Copy number variations (CNVs) and eQTL analyses

We found no significant association of the 7 replicated SNPs known to provide reliable tags for copy number variations (CNVs) in people of European-descent from the Hypergene dataset. For all the SNPs, the calculated correlation was below 0.002. We also explored a list of SNPs tagging CNVs from the GIANT consortium. Out the 7 SNPs tested, only the rs1570669 was in slight linkage disequilibrium ($r^2 = 0.54$) with one SNP of the WTCCC2 list (rs927651). The corresponding SNP tags the CNVR7875.1 CNV located 455b from the SNP of interest.

For each of the 7 replicated SNPs, we identified all proxy SNPs with $r^2 > 0.8$ in HapMap CEU (releases 21, 22, and HapMap 3 version 2) using the online SNAP database (<http://www.broadinstitute.org/mpg/snap/>). This led to the identification of 40 SNPs. We then queried each of these SNPs in the eQTL database of the University of Chicago (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>). Three of the seven SNPs are in strong linkage disequilibrium with an eQTL, as illustrated in **Table S6**.

Information on genes mapping into the replicated genomic regions

Proposed functions of the genes mapping into the associated intervals (± 250 kb) are in **Box 1** and in **Table S7** for the gene-rich *GCKR* region. We report in **Table S8** the mechanism and/or location of all available biological processes, cellular components and molecular functions related to the genes mapping into the associated intervals from the AmiGo 1.8 gene ontology database. We also queried the OMIM database for each genes located within ± 250 kb of the replicated loci (**Table S9**).

Validation across ethnicities

In Indian-Asians, all 7 replicated SNPs had beta-coefficients that were direction-consistent with the primary analysis and 3 were statistically significant ($P < 0.05$): rs1801725 (*CASR*, $P = 1.4\text{E-}31$), rs1550532 (*DGKD*, $P = 0.002$) and rs10491003 (*GATA3*, $P = 0.009$) (**Table S10**). In Japanese, 3 SNPs had betas that were direction-consistent with the primary analysis, but only rs1801725 (*CASR*) was associated with serum calcium ($P = 0.001$) (**Table S10**).

Associations with related phenotypic traits

We conducted analyses of related bone mineral and endocrine phenotypic traits for the 7 replicated loci (**Table 2**). Several SNPs were associated ($P < 0.05$) with bone mineral density (BMD) in the GEFOS consortium [6]: rs1801725 at *CASR* ($P = 0.025$; previously reported [4,5]) and rs780094 (*GCKR*) at the lumbar spine ($P = 0.006$), rs1570669 at *CYP24A1* at the femoral neck ($P = 0.04$), and rs1550532 at *DGKD* at both the lumbar spine ($P = 0.003$) and the femoral neck ($P = 0.003$). For endocrine phenotypes, rs1570669 at *CYP24A1* was associated with higher PTH concentrations ($P = 0.0005$) and rs1801725 at *CASR* with higher serum PTH concentrations ($P = 0.028$) and lower serum phosphate concentrations, as previously reported [4,5]. No SNP was associated significantly with circulating 25-OH vitamin D concentrations (all $P > 0.05$) in the SUNLIGHT consortium [7].

Animal studies

We selected biologically plausible gene(s) at each locus for *in vivo* studies in a mouse model as described in **Methods** section. We

Table 1. Genome-wide significant and replicated loci for serum calcium in Europeans.

Markers*	chr	Position	Nearby Genes	Discovery analysis						Replication analysis						Meta-analysis					
				A1	A2	N	Freq A1	Effect A1	SE	P value	N	Freq A1	Effect A1	SE	P value*	N	Freq A1	Effect A1	SE	P value	
Known locus																					
rs1801725	3	123486447	CASR	t	g	39400	0.15	0.069	0.004	6.5E-59	21654	0.15	0.076	0.007	3.6E-30	61054	0.15	0.071	0.004	8.9E-86	
Novel loci																					
rs1550532	2	233929587	DGKD	c	g	39400	0.31	0.018	0.003	4.6E-08	21598	0.31	0.019	0.005	0.0002	60998	0.31	0.018	0.003	8.2E-11	
rs780094	2	27594741	GCKR	t	c	39400	0.41	0.020	0.003	3.7E-11	21558	0.42	0.008	0.005	0.049	60958	0.42	0.017	0.003	1.3E-10	
rs10491003	10	9368657	GATA3	t	c	38361	0.09	0.027	0.006	1.6E-06	21679	0.10	0.028	0.008	0.0003	60040	0.09	0.027	0.005	4.8E-09	
rs7481584	11	2985665	CARS	a	g	39400	0.29	-0.021	0.003	9.2E-10	21611	0.30	-0.013	0.005	0.008	61011	0.30	-0.018	0.003	1.2E-10	
rs7336933	13	41457076	DGKH; KIAA0564	a	g	39400	0.15	-0.023	0.004	1.6E-07	21528	0.14	-0.022	0.007	0.0009	60928	0.15	-0.022	0.004	9.1E-10	
rs1570669	20	52207834	CYP24A1	a	g	39400	0.66	-0.018	0.003	4.0 E-08	21566	0.66	-0.020	0.005	4.5E-05	60966	0.66	-0.018	0.003	9.1E-12	

P values are corrected for inflation using genomic control. Replication criteria: overall genome-wide significance ($P < 5E-8$) and one-sided replication $P < 0.05$. r^2 was zero for rs1801725, rs1550532, rs10491003, rs7336933 and rs1570669 ($r^2 P > 0.20$). For rs780094 and rs7481584, r^2 were 0.79 and 0.43 with 1^* P 0.03 and 0.19, respectively. For these latter SNPs, sample size weighted meta-analysis P values were 2.93E-10 and 2.03E-10, respectively.

*one-sided P values.

doi:10.1371/journal.pgen.1003796.t001

first analyzed gene expression in the three primary calcium-handling organs: duodenum, kidney and bone (tibia). *CASR* for the rs1801725 locus, *DGKD* for the rs1550532 locus, *GATA3* for the rs10491003 locus, *CARS*, *NAP1L4* and *CDKN1C* for the rs7481584 locus, *DGKH* and *KIAA0564* for the rs7336933 locus, were expressed in all organs, whereas *CYP24A1* (rs1570669 locus) was solely, and *PHLDA2* (rs7481584 locus) mainly, expressed in the kidney (**Figure 2**). No significant expression of *GCKR* (rs780094 locus) was observed in any organ tested, which is of interest considering the strong attenuation of the association of rs780094 with serum calcium after adjustment for albumin (**Table S4**). In micro-dissection of nephron segments [8,9], *DGKD*, *DGKH*, *CARS*, *KIAA0564* and *CYP24A1* were primarily transcribed in the proximal tubule, *CASR* in the thick ascending limb, and *GATA3* predominantly in the distal nephron and collecting duct (**Figure 3**).

In order to determine regulation of gene expression by calcium intake, we measured gene expression levels in mice fed low and high calcium diets (0.17% vs. 1.69% calcium) for one week, with normal diet as control (0.82%) (**Figure 4 and Table S11**). In the kidney, both *DGKD* and *DGKH* were upregulated in response to low calcium diet ($P \leq 0.05$; **Figure 4**). In the tibia, *CASR* was markedly upregulated in response to low calcium diet (2.5-fold increased expression), as were *GATA3*, *KIAA0564* and *CARS* ($P \leq 0.05$ for all; **Figure 4**), findings that suggest regulation by 1,25(OH)²-D. *DGKD* and *DGKH* were upregulated in the tibia in response to high and low calcium diet ($P \leq 0.05$ for all; **Figure 4**). The expression in duodenum of the majority of genes was not modified by dietary calcium, with the exception of *NAP1L4* and *CDKN1C*.

Discussion

We have identified and replicated one known and six new loci for serum calcium near genes linked to bone metabolism and endocrine control of calcium. Of these, 4 loci (*DGKD*, *GCKR*, *CASR*, and *CYP24A1*) were nominally associated with BMD in the general population. In supporting mouse studies, we demonstrate expression of several of these genes in tibia, and show regulation of gene expression in response to dietary calcium intake. We also demonstrate expression in nephron segments known to regulate calcium homeostasis. Taken together, these results shed new light on the genetics of calcium balance.

The vast majority of total body calcium is bound in the skeleton as hydroxyapatite and other calcium-phosphate complexes [10]. Apart from providing skeletal strength, bone serves as a calcium reservoir to maintain tightly controlled circulating concentrations vital to cellular signaling, muscle contraction and coagulation [10]. However, the genetic basis of the dynamic cross talk that occurs between these compartments is poorly understood. Our results advance our understanding in this area. Eight genes identified in the GWAS are constitutively expressed in bone and are regulated in response to dietary calcium, in particular low calcium diet, whereas no clear change was observed in kidney or duodenum. This bone reactivity in response to dietary calcium intake is consistent with what was recently reported for *CASR* [11]. Further, of the eight genes expressed in bone and regulated in response to dietary calcium, we show that rs1550532 (*DGKD*) and rs1801725 (*CASR*) are associated with BMD in humans, the primary determinant of fracture risk.

The A allele of rs1570669 (*CYP24A1* locus) was associated with reduced BMD at the femoral neck although *CYP24A1* was not found to be expressed in bone in mice experiment, which suggests an indirect role in bone mineralization. This may occur via its




Figure 1. Genome-wide association for serum calcium in discovery analysis in Europeans. Manhattan plot showing $-\log_{10}(P)$ values for all SNPs in the discovery GWAS for uncorrected serum calcium in Europeans ($N = 39,400$), ordered by chromosomal position. The plot is truncated at $-\log_{10} P$ values of 10 (truncated $-\log_{10} P$ values for GSKR and CASR). The values correspond to the association of uncorrected serum calcium, including age and sex as covariates in the model as well as study-specific covariates if needed. The gene closest to the SNP with the lowest P value is listed at each locus. Six loci reached genome-wide significance ($P < 5E-08$) at discovery analysis (GSKR, DGKD, CASR, VKORC1L1 (in grey on chromosome 7), CARS and CYP24A1). The seven loci that reached genome-wide significance at the combined analysis following replication are highlighted in red (GSKR, DGKD, CASR, GATA3, CARS, DGKH-KIAA0564 and CYP24A1). doi:10.1371/journal.pgen.1003796.g001

documented role in vitamin D metabolism, discussed below, and/or its association with higher PTH concentrations identified in the present analysis.

We observed specific expression patterns of several genes in the mouse nephron: *DGKD*, *DGKH*, *CARS*, *KIAA0564* and *CYP24A1* were primarily transcribed in the proximal tubule, *CASR* expression was mostly localized to the thick ascending limb, whereas *GATA3* was predominantly found in the distal part of the nephron and the collecting duct. This pattern of expression in segments known to be involved in calcium reabsorption suggests a role in renal calcium handling and is consistent with previous exploratory transcriptome analyses in humans and mice [12,13]. Both *DGKD* and *DGKH* were significantly upregulated in the kidney in response to low calcium diet, suggesting specific involvement of these genes in renal calcium handling.

Several of the newly identified loci harbor genes linked to the hormonal control of serum calcium. First, the association of *CASR* with PTH concentrations is consistent with its known role in PTH signaling. Second, several lines of evidence implicate rs1570669 (*CYP24A1*) in the vitamin D pathway: its association with serum calcium and PTH concentrations, its selective expression in the proximal tubule where 1,25(OH)₂D metabolism occurs, and that loss-of-function *CYP24A1* mutations cause vitamin D-induced hypercalcemia in children (idiopathic infantile hypercalcemia). Third, we identified variants linked to 2 chromosomally distinct isoforms of diacylglycerol kinase, part of the phosphoinositide second messenger system, that may interact with each other at the protein level [14,15].

Strengths of this study are the large sample size and consistent mouse studies to support the statistical associations and advance our knowledge of the biology at these loci. Human and mice largely share physiological processes linked to calcium metabolism, including tissue-specific gene expression. Limitations include the lack of a direct marker of bone remodeling and the potential for bias in gene selection for experimental follow-up. Mice may display subtle differences in the regulation of the genes tested compared to humans.

We have identified and replicated one known and six new loci for serum calcium near genes linked to bone metabolism and endocrine control of serum calcium. Supporting experimental mouse studies suggest a role for dietary calcium in bone-specific gene expression. Further work is needed to identify the causal variants and to understand how they influence calcium homeostasis.

Materials and Methods

Ethics statement

In each human study, the local institutional review board approved the study and participants signed written informed consent, including for DNA analyses. The experimental protocol in mice was approved by the local veterinarian authorities and fulfilled Swiss federal regulations for experiences with animals.

Participating studies (human data)

Discovery and replication cohorts. A list of all discovery and replication studies, their sample size, mean serum calcium levels, age and serum albumin as well as proportion of women can be found in **Table S1**. We replicated findings using *de novo* genotyping in the Bus Santé Study and *in silico* data in all other cohorts. In most studies, serum calcium was measured using a colorimetric assay. The size of discovery tables varied from 488 to 9,049 for a total of 39,400 participants. A detailed description of the characteristics of discovery and replication cohorts, including laboratory method for serum calcium measurement, can be found in **Table S12**.

Genotyping

Detailed information on the genotyping platforms and data cleaning procedures for each discovery and replication cohort can be found in **Table S13**. *De novo* replication genotyping was performed in 4670 participants to the Bus Santé Study using KASPar v4.0 after whole genome amplification by primer extension pre-amplification (PEP) using thermostable DNA polymerases.

Table 2. Look-ups of serum calcium loci with related phenotypes: bone mineral density in the GEFOS dataset [6] and endocrine phenotypes from the SHIP, SHIP Trend and SUNLIGHT [7] datasets.

Markers		Lumbar bone density			Femoral bone density			Serum phosphorus			25OH Vitamin D			Parathyroid hormone							
		A1	N	Effect A1 SE	P value	N	Effect A1 SE	P value	N	Effect A1 SE	P value	N	zscore	P value	N	Effect A1 SE	P value				
rs1801725	CASR	T	31791	-0.029	0.013	0.03	32948	-0.011	0.012	0.4	16190	-0.038	0.008	3.4E-07	22537	-0.426	0.7	4181	0.031	0.014	0.03
	DGKD	C	31681	-0.028	0.009	0.003	32845	-0.025	0.009	0.003	16190	-0.013	0.006	0.03	20371	-0.888	0.4	4181	0.032	0.010	0.002
rs1550532	GCKR	T	31783	-0.024	0.009	0.006	32946	-0.009	0.008	0.3	16190	0.011	0.005	0.03	22520	-0.699	0.5	4181	0.0002	0.010	1.0
	rs780094	T	31797	0.007	0.016	0.6	32740	0.015	0.015	0.3	16190	-0.001	0.010	0.9	22543	-1.328	0.2	4181	0.018	0.018	0.3
rs10491003	GATA3	A	31667	0.013	0.009	0.2	32948	0.006	0.009	0.5	16190	0.011	0.006	0.08	20366	-1.630	0.1	4181	-0.006	0.011	0.6
	rs7481584	A	30992	-0.006	0.013	0.7	32152	0.000	0.012	1.0	16190	0.0115	0.008	0.1	20437	0.648	0.5	4181	-0.010	0.013	0.4
rs7336933	DGKH	A	31739	-0.004	0.009	0.7	32900	-0.017	0.009	0.04	16190	0.0040	0.006	0.5	20385	0.144	0.9	4181	0.035	0.010	0.0005
	rs336933	A																			
rs1570669	CYP24A1	A																			
	rs1570669	A																			

NA, not available. P values < 0.05 were considered as statistically significant. A1, effect allele. β , regression coefficient for allele A1, SE, standard error. P, two-sided P value. Zscore, z score.
doi:10.1371/journal.pgen.1003796.t002

Statistical analyses for the genome-wide association meta-analysis

In each discovery study, genotyping was performed using a genome-wide chip and nearly 2.5 million SNPs were genotyped or imputed using the HapMap CEU panels release 22 or 21 as the reference. Each study applied quality control before imputation. Detailed imputation information is provided in **Table S13**. Each SNP was modeled using an additive genetic effect (allele dosage for imputed SNPs), including age and sex as covariates in the model as well as study-specific covariates if needed (e.g. principal components, study center). The primary dependent variable in each discovery study was untransformed and uncorrected serum calcium expressed in mg/dL. Beta regression coefficients and standard errors were used with at least 5 decimal places. For secondary analyses, albumin-corrected serum calcium was computed using the following formula: $([4\text{-plasma albumin in g/dL}] \times 0.8 + \text{serum calcium in mg/dL})$ and the same model as for the primary analyses was used. Each file of genome-wide summary statistics underwent extensive quality control prior to meta-analysis both for primary and secondary analyses, including (1) boxplots of all beta coefficients, as well as all standard errors multiplied by the square-root of the sample size, for each study separately; (2) the range of P values, MAF, imputation qualities, call rates and Hardy-Weinberg equilibrium P values and (3) QQ plots. In addition, we checked the direction and magnitude of effect at the previously reported rs1801725 *CASR* variant. Genome-wide meta-analyses were conducted in duplicate by two independent analysts. For each SNP, we used a fixed effect meta-analysis using inverse-variance weights as implemented in the meta-analysis utility Metal [16]. Results were confirmed by a z-score based meta-analysis. Data were available for 2,612,817 genotyped or imputed autosomal SNPs for the primary and secondary analyses. After the meta-analysis, genomic control correction was applied (λ_{GC} was 1.03 for both uncorrected and corrected serum calcium). Our pre-specified criterion to declare genome-wide significance was $P \text{ value} < 5E-8$ to account for 1 million independent tests according to the Bonferroni correction. We choose to move forward for replication all SNPs with discovery $P \text{ value} < 1E-7$ in the European sample or genome-wide significant SNP in the overall sample that included Indian Asians. To choose a single SNP per genome-wide associated region for replication, we merged all SNPs within 1 Mb region and selected the lowest P value for each region. Altogether, fourteen SNPs were moved forward for replication. Up to 17,205 participants contributed information to the replication analyses *in silico* and 4,670 participants provided data for *de novo* genotyping. We used fixed-effects inverse-variance weighted meta-analysis to combine discovery and replication meta-analysis results. Replication was considered as present whenever a combined $P \text{ value} < 5E-8$ together with an effect-concordant one-sided replication $P \text{ value} < 0.05$ were obtained.

Data for look-ups of serum calcium loci with related phenotypes

We conducted look-ups for femoral and lumbar bone density in the GENetic Factors of Osteoporosis (GEFOS) dataset [17]. Bone mineral density (BMD) is used in clinical practice for the diagnosis of osteoporosis and bone density at different skeletal sites is predictive of fracture risk. BMD was measured in all cohorts at the lumbar spine (either at L1–L4 or L2–L4) and femoral neck using dual-energy X-ray absorptiometry following standard manufacturer protocols [17]. Serum phosphorus was looked up from a




Figure 2. Relative mRNA expression of replicated genes in three calcium-transporting tissues (kidney, duodenum, tibia). The expression (based on delta CT [cycle threshold] normalized to actin) of the selected genes is compared to the expression of the *CASR* gene in the duodenum, thereby providing a relative expression. Cut-off was set at delta CT ≤ 15 . Data are means \pm standard error of the mean (SEM) of values obtained from 5 mice fed a normal diet. *GCKR* was not expressed. doi:10.1371/journal.pgen.1003796.g002

previously published GWAS meta-analysis, including 16,264 participants of European ancestry [18]. Serum phosphorus concentrations were quantified using an automated platform in which inorganic phosphorus reacts with ammonium molybdate in an acidic solution to form a colored phosphomolybdate

complex [18]. The 25-hydroxyvitamin D was looked-up in the SUNLIGHT consortium [7], which includes data from 33,996 individuals of European descent from 15 cohorts. 25-hydroxyvitamin D concentrations were measured by radioimmunoassay, chemiluminescent assay, ELISA, or mass spectrometry




Figure 3. Relative mRNA expression of identified genes in kidney tubule segments. The renal tubular segments analyzed were the proximal tubule (PROX), the thick ascending limb of the loop of Henle (TAL), the distal convoluted tubule and connecting tubule (DCT-CNT), and the cortical collecting duct (CCD). The expression (based on the delta CT [cycle threshold]) of the selected genes is compared to the expression of the *CASR* gene in the PROX, thereby providing a relative expression. Data are means of values obtained from 3 mice fed a normal diet. *GCKR* was not expressed. doi:10.1371/journal.pgen.1003796.g003






Figure 4. Relative mRNA expression of identified genes from mice fed a low (0.17%) and high (1.69%) calcium diet compared to mice fed a normal calcium diet (0.82%). Data are means \pm SEM of values obtained from 5 mice for each diet group. Expression levels were normalized to actin. Statistical significance of the difference between diets was calculated using unpaired t-test. *: $P \leq 0.05$ (low compared to high); #: $P \leq 0.05$ (low compared to normal); # $P \leq 0.05$ (high compared to normal). doi:10.1371/journal.pgen.1003796.g004

[7]. PTH was looked-up in the SHIP and SHIP-Trend studies. The serum parathyroid hormone concentration was measured on the IDS-iSYS Multi-Discipline Automated Analyser with the IDS-iSYS Intact PTH assay (Immunodiagnostic Systems Limited, Frankfurt am Main, Germany) according to the instructions for use. This chemiluminescence immunoassay detects the full-length parathyroid hormone (amino acids 1–84) and the large parathyroid hormone fragment (amino acids 7–84). The measurement range of the assay was 5–5000 pg/mL. The limits of blank, detection and quantitation were 1.3 pg/mL, 1.4 pg/mL, and 3.6 pg/mL, respectively. As recommended by the manufacturer, three levels of control material were measured in order to verify a decent working mode. During the course of the study, the coefficients of variation were 14.02% at low, 6.64% at medium, and 6.84% at high serum parathyroid hormone concentrations in the control material in SHIP and the corresponding percentages were 16.8% at low, 10.7% at medium, and 9.0% at high serum parathyroid hormone concentrations in the control material in SHIP-Trend.

Copy Number Variation (CNV) analysis

The Hyergene dataset (a 4206 samples case-control study concerning hypertension genotyped using the Illumina 1M chip) has been used to call CNVs and to check their correlation with the SNPs of interest. The CNVs calls have been done using pennCNV software [19]. A SNP by sample matrix with the copy number status was created. Then the square correlation (Pearson correlation) between value of each SNP of interest and the SNPs copy number status in a ± 2 Mb region was calculated. The SNPs of interest for which no correspondence has been found in the Hyergene dataset have been replaced by the closest SNPs in high linkage disequilibrium (LD) and present in the Hyergene dataset. LD between the SNPs of interest and a list of SNPs tagging CNVs from the GIANT consortium has also been calculated. The SNPs from the GIANT list are in LD higher than 0.8 with their corresponding CNV.

Gene ontology classification analysis

We queried the AmiGo 1.8 gene ontology database for each gene located within ± 250 kb of the seven replicated SNPs, including rs1801725 (*CASR*). (<http://amigo.geneontology.org/cgi-bin/amigo/go.cgi>, last accessed November 6, 2012). We used *Homo sapiens* as a filter for species.

Expression quantitative trait locus (eQTL) Analyses

For each of the 7 replicated SNPs, we identified all proxy SNPs with $r^2 > 0.8$ in HapMap CEU (releases 21, 22, and HapMap 3 vers. 2) using the online SNAP database (<http://www.broadinstitute.org/mpg/snap/>). We then queried each of these 40 SNPs in the eQTL database of the University of Chicago (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>).

Rationale for gene selection for experimental analyses in mouse

The rs1801725 SNP encodes a missense variant in exon 7 of the *CASR* gene leading to an alanine to serine substitution (A986S). Given the key physiological role of *CASR* in calcium

homeostasis (monogenic disorders of calcium balance), this gene was the logical candidate for analysis in mouse at this previously identified locus.

For the 6 newly identified loci, the precise rationale for gene selection varied from one locus to the other, but the main criteria was to focus on the most biologically relevant gene. Rs1550532 on chromosome 2 is an intronic SNP of *DGKD*, which was the most likely biological candidate for this locus and was therefore selected for analysis in mouse. None of the other genes located in this region (± 250 Kb) has a known link with calcium homeostasis (**Box 1**) and rs1550532 is not in strong linkage disequilibrium with an eQTL (**Table S6**). We also took into account the fact that another member of the DGK family, namely DGKH was located near one of the other replicated loci, on chromosome 13.

Rs780094, on chromosome 2, is located in intron 16 of *GCKR* and is in strong linkage disequilibrium ($r^2 = 0.93$) in Caucasians [20], with a common non-synonymous SNP (P446L, rs1260326) associated with glucokinase activity *in vitro* [20,21]. This SNP has been associated with multiple other phenotypes in previous GWAS and it is in strong linkage disequilibrium with an eQTL (**Table S6**). Previous fine mapping analysis of this locus has attributed the signal from rs780094 to the functional rs1260326 variant [20]. The *GCKR* locus may indirectly influence calcium concentrations via its association with albumin levels [22]. In line with this, we observed an attenuation of the association of rs780094 with albumin-corrected serum calcium compared to the association with uncorrected serum calcium and we found *GCKR* not to be expressed in any of the key organs involved in calcium homeostasis that we tested in mice. We selected *GCKR* for analysis in mouse at this locus.

Rs10491003 on chromosome 10 is located within a long non-coding RNA. For this locus, we selected *GATA3*, the nearest and only gene located within this region, for analysis in mouse. *GATA3* is implicated in monogenic disorders of calcium balance.

Rs7481584 is located within *CARS* (intronic SNP) in an imprinted region known to play a role in multiple cancers, which makes this locus a plausible candidate for malignancy-related hypercalcemia. Other plausible biological candidates in this locus are *NAP1L4*, *PHLDA2* and *CKDN1C* (**Box 1**). Rs7481584 is in strong LD with 2 eQTLs, one associated with the expression of *NAP1L4* (rs2583435) and the other one associated with the expressions of *SLC22A18* and *SLC22A18AS*. We selected *CARS*, *NAP1L4*, *PHLDA2* and *CKDN1C* for analyses in mouse.

For rs7336933, we selected the two only genes (*DGKH* and *KIAA0564*) located under this association peak on chromosome 13 for analyses in mouse.

Finally, rs1570669 is an intronic SNP of *CYP24A1*, a strong biological candidate implicated in monogenic disorders of calcium balance. The two other genes of this region (*BCAS1* and *PFDN4*) have no known link with calcium homeostasis. Furthermore, rs1570669 and *PFDN4* are separated by a recombination hot spot. We selected *CYP24A1* for analysis in mouse.

As animal experiments started while the replication process was underway, we had also initially selected the following genes for analysis in mouse: *RSG14* and *SLC34A1* at locus rs4074995 (discovery P value = 2.4×10^{-7}), *VKORC1L1* at locus rs17711722 (discovery P value = 2.8×10^{-11}), *PTGB* at locus rs2281558 (discovery

Box 1. Genes Located within Replicated Loci for Serum Calcium

We here summarize the information on genes located within ± 250 kb from the top SNP at each locus. Because it is a gene dense region, details of genes located in the *GCKR* genomic region are presented in **Table S4**.

Chromosome 2, locus rs1550532

DGKD rs1550532 is an intronic SNP located near the 5'UTR region of *DGKD*. *DGKD* encodes diacylglycerol kinase delta, a member of the diacylglycerol kinase (DGK) enzyme family. Alternative splicing of the *DGKD* gene results in two isoforms, which differ in their expression profiles and regulatory mechanisms [24]. DGKs play an important role in signal transduction by modulating the balance between the diacylglycerol (DAG) and phosphatidic acid (PA), important second messengers in signaling cascades. Recent findings suggest that DAG is involved in calcium signaling in parathyroid cells [25]. *CASR* signaling influences intracellular DAG levels in cardiomyocytes [26].

SAG encodes S-antigen (also called arrestin), a soluble photoreceptor protein expressed in the retina and pineal gland. Mutations in this gene are associated with Oguchi disease (OMIM#258100), a rare autosomal recessive form of night blindness. Arrestin is a calcium-binding protein that plays an important role in phototransduction.

ATG16L1 encodes autophagy related 16-like 1 protein, part of a complex involved in autophagia. Mutations in this gene are responsible for inflammatory bowel disease 10 (OMIM # 611081). There is no known direct link with calcium signaling.

SCARNAS and SCARNA6 encode small Cajal body-specific RNAs 5 and 6, which are small nuclear RNAs, belonging to non-coding RNAs involved in the RNA-processing machinery. There is no known direct link with calcium signaling.

USP40 encodes ubiquitin specific peptidase 40. USP40 functions as a deubiquinating enzyme involved in the degradation of unwanted intracellular proteins in eukaryotic cells. There is no known direct link with calcium signaling.

INPP5D encode inositol polyphosphate-5-phosphatase, expressed in hematopoietic cells. This protein regulates myeloid cell proliferation. The presence of a recombination peak between this gene and rs1550532 makes it an unlikely candidate for this signal.

Chromosome 10, locus rs10491003

rs10491003, located within a long non-coding RNA with *GATA3* as its nearest gene may influence the expression of *GATA3* [27].

GATA3: *GATA3* encodes a GATA transcription factor involved in T cell lymphopoiesis [28], renal and vestibular morphogenesis [29,30], and parathyroid gland development [31]. *GATA3* haploinsufficiency causes hypoparathyroidism and hypocalcemia in the autosomal dominant HDR syndrome (hypoparathyroidism, sensorineural deafness and renal dysplasia) (OMIM#146255) [32,33]. Although *GATA3* is the closest gene to rs10491003, this variant lies 1.2 Mbp downstream from that gene. However, *GATA3* has a very large flanking regulatory region - greater than 450 kbp - [34] and mammalian enhancers may lie more than 1 Mbp away from the gene they regulate [35]. *GATA3* may play a role in preserving high degree of differentiation of parathyroid gland and of calcium transporting epithelia [36].

Chromosome 11, locus rs7481584

This region is located in the imprinted gene domain of 11p15.5, an important tumor suppressor gene region [37].

CARS: rs7481584 is an intronic SNP of *CARS*. *CARS* encodes a cysteinyl-tRNA synthetase and is located within the imprinted gene domain of 11p15.5. This region is linked to Beckwith-Wiedemann syndrome, which is associated with hypocalcemia and hypercalciuria.

NAP1L4 encodes nucleosome assembly protein 1-like 4, a member of the nucleosome assembly protein, potentially involved in histone chaperoning and ubiquitously expressed. NAP1L1 and NAP1L4 have been recently identified as being involved in the regulation of DGKH nucleocytoplasmic shuttling [38]. A link with calcium homeostasis could be possible via the DGKs pathway.

PHLDA2 encodes pleckstrin homology-like domain, family A, member 2. This gene has been recently highlighted as potentially relevant for osteoporosis on the basis of a bioinformatics pathway analysis approach [39]. Imprinting of this gene appears to play a role in fetal growth, including fetal bone growth, birth weight and bone mass in childhood.[40,41,42,43] In cancer, *PHLDA2* is activated by parathyroid hormone-like hormone (PTHrH) [44]. *PTHrH* is associated with malignancy-related hypercalcemia [45], lactation [46], the expression of *PHLDA2* is upregulated in osteosarcoma progression [47].

OSBPL5 encodes oxysterol binding protein-like 5, an intracellular lipid receptor involved in cholesterol balance. There is no known direct link with calcium homeostasis.

MRGPRE and MRGPRG encode MAS-related G-protein-coupled receptors, member E and G. This family of receptors is expressed in nociceptive sensory neurons. There is no known direct link with calcium homeostasis.

C11orf36 encodes MRGPRG antisense RNA 1. Little is known about this gene.

SNORA54 encodes small nucleolar RNA, H/ACA box. The gene product belongs to non-coding RNAs involved in the RNA-processing machinery. There is no known direct link with calcium homeostasis.

SLC22A18 and SLC22A18AS encode solute carrier family 22, member 1 and solute carrier family 22, member 1 antisense. *SLC22A18* is an organic cation transporter. Mutations in *SLC22A18* have been found in several cancers. There is no known direct link with calcium homeostasis.

CDKN1C encodes cyclin-dependent kinase inhibitor 1C (p57, Kip2), a protein involved in cell-cycle progression. This imprinted gene is responsible for the IMAGe syndrome (OMIM#300290) characterized by intrauterine growth restriction, metaphyseal dysplasia, delayed bone aging, adrenal hypoplasia congenital, genital anomalies, and sometimes hypercalciuria [48].

KCNQ1 encode potassium voltage-gated channel, KQT-like subfamily, member 1. *KCNQ1OT1* represents *KCNQ1* opposite strand transcript 1 and is an unspliced long non-coding RNA, which regulates the transcription of many target genes. Mutations in *KCNQ1* are associated with hereditary long and short QT syndromes (OMIM#192500 & 609621), Jervell and Lange-Nielsen syndrome (OMIM#220400), familial atrial fibrillation (OMIM#607554), type 2 diabetes. *KCNQ1* is also imprinted in a tissue-specific manner. There is no known direct link with calcium homeostasis.

Chromosome 13, locus rs7336933

DGKH encodes diacylglycerol kinase eta, a member of the diacylglycerol kinase (DGK) enzyme family. See *DGKD* (above) for discussion.

KIAA0564: this gene encodes a large uncharacterized protein containing a putative ATP-ase domain. The sequence of this gene is conserved across a large array of organisms,

from humans to mouse, zebrafish and to *C. elegans*, which suggests an important biological function. Yet, little is known on the nature of the function of this gene so far.

Chromosome 20, locus rs1570669

CYP24A1: rs1570669 is an intronic SNP of *CYP24A1*. *CYP24A1* encodes a cytochrome P450 enzyme that hydroxylates 1,25-(OH)₂D, into metabolites targeted for degradation and appears to be one of the central regulator of 1,25-(OH)₂D metabolism. *CYP24A1* is highly regulated by its own substrate 1,25-(OH)₂D, as well as by PTH [49,50], serum

phosphate and fibroblast growth factor-23 (FGF-23) [51,52,53]. Sequence variants of *CYP24A1* impacting on 1,25-(OH)₂D metabolism have been described recently and explain the strong heritability of 1,25-(OH)₂D concentrations. *BCAS1* encodes breast carcinoma amplified sequence 1, considered as an oncogene. *BCAS1* is highly differentially expressed in some cancers. However, there is no direct link with calcium homeostasis.

PFDN4 encodes prefoldin subunit4. Prefoldin is a chaperone complex involved in polypeptide folding. There is no known link of this gene with calcium homeostasis.

P value = 6.4E-07), *CD109* at locus rs9447004 (discovery P value = 8.1E-06). No gene was selected for the rs2885836 and rs11967485 and rs12150338 loci in the absence of obvious candidate. Results for these unreplicated loci can be found in **Figures S6, S7 and S8**. We present these results for quality control purposes: *SLC34A1* (also known as NAPI-3 or NPT2), which encodes solute carrier family 34 (sodium phosphate), member 1, was expressed in the kidney, but neither in duodenum nor in bone, as expected based on current knowledge on this phosphate transporter. In the kidney *SLC34A1* was mainly expressed proximally and *SLC34A1* expression was upregulated under low calcium diet, which is in line with the known function of this gene.

Mouse experiments

Five C57Bl/6 mice (Janvier) per group were fed, for one week, three different diets in which the percentage of calcium were 0.17% (low calcium diet), 0.82% (normal calcium diet) and 1.69% (high calcium diet) and had free access to water. 12:12 hours light/dark alternance was imposed. At the end of the week of the specific diet, spot urine were collected and mice were anesthetized. Blood was collected by retro-orbital puncture. Organs were immediately harvested and snap frozen. RNA was extracted using Trizol (Invitrogen) and reversed transcribed with PrimeScript™ RT reagent Kit (Takara Bio Inc). Calcium, sodium, phosphate and creatinine in plasma and urine were analyzed at the central lab of the Lausanne University hospital using a Cobas-Mira analyzer (Roche).

Microdissection. A separate set of three mice was kept under normal calcium diet. Proximal Tubule (Prox), thick ascending limb of the loop of Henle (TAL), distal convoluted tubule and connecting tubule (DCT-CNT) and cortical collecting duct (CCD) were isolated by microdissection of the left kidney after the mice were perfused with Liberase TM (Roche Diagnostics) [23]. RNA was extracted from the above mentioned tubules following TRI Reagent Solution protocol (Applied Biosystems) and purified with RNeasy Micro Kit (Qiagen). Reversed transcription was performed with PrimeScript™ RT reagent Kit (Takara Bio Inc). Quantitative PCRs were performed (7500 Software v 2.0.4.) using TaqMan gene expression assays for the different genes (Applied Biosystems) and comparative CT method was applied. Expression levels were normalised to beta actin as endogenous reference gene.

Statistics. Comparison of groups was performed using unpaired Student's t-test.

Supporting Information

Figure S1 QQ-plot of uncorrected serum calcium GWAS meta-analysis. Quantile-quantile plot showing observed p-values of the

uncorrected serum calcium meta-analysis vs. expected p values by chance. The second genomic control step was applied to correct for the post meta-analysis of $\lambda = 1.03$.

(PDF)

Figure S2 Regional association plot for the *CASR* locus. Regional association plot showing $-\log_{10}$ p-values for the association of all SNPs ordered by their chromosomal position with uncorrected serum calcium at the *CASR* loci. The $-\log_{10}$ P value for each SNP is colored according to the correlation of the corresponding SNP with the SNP showing the lowest p-value (index SNP) within the locus using different colors for selected levels of linkage disequilibrium (r^2). Correlation structures correspond to HapMap 2 CEU.

(PDF)

Figure S3 Regional association plot for the newly identified loci. Regional association plot showing $-\log_{10}$ p-values for the association of all SNPs ordered by their chromosomal position with uncorrected serum calcium within the replicated loci. The $-\log_{10}$ P value for each SNP is colored according to the correlation of the corresponding SNP with the SNP showing the lowest p-value (index SNP) within the locus using different colors for selected levels of linkage disequilibrium (r^2). Correlation structures correspond to HapMap 2 CEU.

(PDF)

Figure S4 Manhattan plot of corrected serum calcium. Manhattan plot showing $-\log_{10}$ (P values) for all SNPs analyzed, ordered by their chromosomal position. The values correspond to the association of albumin-corrected serum calcium, including age and sex as covariates in the model as well as study-specific covariates if needed.

(PDF)

Figure S5 QQ-plot of corrected serum calcium. Quantile-quantile plot showing observed p-values of the corrected serum calcium meta-analysis vs. expected P values by chance in Europeans at discovery. The second genomic control step was applied to correct for the post meta-analysis of $\lambda = 1.03$.

(PDF)

Figure S6 Relative expression of genes in non-replicated loci in kidney, duodenum and tibia. The expression (based on delta CT normalized to actin) of the selected genes is compared to the expression of the *CASR* gene in the duodenum, thereby providing a relative expression. Cut-off was set at delta CT ≤ 15 . Data are means \pm SEM of values obtained from 5 mice fed a normal diet.

(PDF)

Figure S7 Relative expression in segments of kidney tubules of genes located in non-replication loci. The renal tubular segments analyzed were the proximal tubule (PROX), the thick ascending

limb of the loop of Henle (TAL), the distal convoluted tubule and connecting tubule (DCT-CNT), and the cortical collecting duct (CCD). The expression (based on the delta CT) of the selected genes is compared to the expression of the *CASR* gene in the PROX. Data are means of values obtained from 3 mice fed a normal diet. *GCKR* was not expressed.
(PDF)

Figure S8 Relative expression of genes in non-replicated loci under various calcium diets. Data are means \pm SEM of values obtained from 5 mice fed a low (0.17%) and high (1.69%) calcium diet compared to mice fed a normal calcium diet (0.82%). Expression levels were normalized to actin. Statistical difference was calculated using unpaired t-test. *: P value \leq 0.05 (low compared to high); ‡: P value \leq 0.05 (low compared to normal); #: P value \leq 0.05 (high compared to normal).
(PDF)

Table S1 Characteristics of study participants in discovery and replication cohorts. Data are mean (SD) unless otherwise specified for each discovery and replication studies.
(DOCX)

Table S2 SNPs brought forward for replication that did not replicate. Chr, chromosome. A1, effect allele. A2, non-effect allele. Effect A1, regression coefficient for the A1 allele. SE, standard error. Freq A1, frequency of allele A1.
(DOCX)

Table S3 SNPs with P value $< 5 \times 10^{-5}$ for uncorrected calcium in Europeans (discovery). Chr, chromosome. Position, position on build 36. A1, allele 1 (effect allele). A2, allele 2. Freq A1, frequency of allele 1. InRefGen, gene symbol if SNP is located within a specific gene.
(DOCX)

Table S4 Comparison of association with uncorrected versus corrected serum calcium. Chr, chromosome. Freq A1, frequency of allele A1. Beta, regression coefficient for the A1 allele. SE, standard error. A1, allele 1 (effect allele). Only replicated loci are included in this table.
(DOCX)

Table S5 Genome-wide significant loci for corrected calcium in Europeans (discovery). Chr, chromosome. Position, position on build 36. A1, allele 1 (effect allele). A2, allele 2. Freq A1, frequency of allele 1. InRefGen, gene symbol if SNP is located within a specific gene.
(DOCX)

Table S6 eQTL analysis for the seven genome-wide replicated loci for serum calcium. We used the online eQTL database of the University of Chicago (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>, last accessed, November 5, 2012). All eQTL were acting in *cis*.
(DOCX)

Table S7 Details on genes located in the GCKR genomic region.
(DOCX)

Table S8 Gene Ontology classification (AmiGo). Data are GO numbers, ontology and mechanism/location from the AmiGo

1.8 gene ontology database for each gene located within ± 250 kb of the seven replicated SNPs, including rs1801725 (*CASR*).
(DOCX)

Table S9 OMIM disorders associated with the genes located within the replicated loci. This table includes all Mendelian disorders or other types of genetic disorders included in the OMIM database described for each gene located within ± 250 kb of any of the six new loci and for *CASR*.
(DOCX)

Table S10 Association of replicated serum calcium loci in other ethnic groups. Chr, chromosome. Position, position on build 36. A1, allele 1 (effect allele). A2, allele 2. Freq A1, frequency of allele 1. Effect A1, regression coefficient for the A1 allele. SE, standard error. NA, not available.
(DOCX)

Table S11 Plasma and Urine electrolytes values by calcium diet in mice. Data are means \pm SEM of values obtained from 3 to 5 mice. *: P value \leq 0.05 compared to normal or high calcium diet.
(DOCX)

Table S12 Study information.
(DOCX)

Table S13 Genotyping information for each cohort (discovery, replication and look-ups).
(DOCX)

Text S1 Study specific acknowledgements.
(DOCX)

Acknowledgments

The full list of acknowledgments for each study is provided in the Supporting Information files (**Text S1**).

Author Contributions

Conceived and designed the experiments: CMOS HWu QY KK WHLK HWa OB CSF MBoc. Performed the experiments: CMOS HWu QY KK IG AMZ AK CSt ZK TH GE LJL VG DEA LF DSS BMP OHF AHo AGU JCMW IJD JMS MP EMB PV SBe CH VV SBa IR OP JW HC JSK JCC AHa CSc MN RB UV PBM MJB JMT JMG TDS WH APM LL WM BOB BRW CG CM WHLK HWa OB CSF MBoc. Analyzed the data: CMOS HWu QY KK IG AMZ AK AT ZK YL TH JD KL AVS GE LJL VG TT GL AD FR LML LP FM JH AMac SBe CH VV JFW WZ AHo AGU FR KE SP MM FDE AMah WH APM MEK ACB CG WHLK HWa OB CSF MBoc. Contributed reagents/materials/analysis tools: IG YL VG EB DH AS DSS BMP AGU FR IJD JMS MP PV GD VV CH JSK JCC PBM MM SYS APM MEK TM WHLK HWa CSF MBoc. Wrote the paper: CMOS IG AK HWa OB CSF MBoc. Revising and reviewing the manuscript for important intellectual content: CMOS HWu QY KK IG AMZ AK CSt AT ZK MM AD WZ GE GL TT LP LML CH KL KM SP DF RS SU ACB MEK AMah FDE VG LJL AMac EB DEA CT YN MJB JMG JMT DSS BMP SBe PV VV AFW TZ MBob IK PN EMB KE JD TBH SBa DH ABS GG DR APA AR TM CM GD JMS JCC BOB BRW JH FM SHW HC APM OHF AHo AGU FR UV AHa RB WH SYS PL HH CSc PBM PG NP MC CG WM LL TDS AVS IR JFW OP IJD MP LF YL BK JSK JCMW MN WHLK HWa OB CSF MBoc.

References

- Whitfield JB, Martin NG (1984) The effects of inheritance on constituents of plasma: a twin study on some biochemical variables. *Ann Clin Biochem* 21 (Pt 3): 176–183.
- Williams PD, Puddey IB, Martin NG, Beilin LJ (1992) Platelet cytosolic free calcium concentration, total plasma calcium concentration and blood pressure in human twins: a genetic analysis. *Clin Sci (Lond)* 82: 493–504.

3. Hunter DJ, Lange M, Snieder H, MacGregor AJ, Swaminathan R, et al. (2002) Genetic contribution to renal function and electrolyte balance: a twin study. *Clin Sci (Lond)* 103: 259–265.
4. O'Seaghdha CM, Yang Q, Glazer NL, Leak TS, Dehghan A, et al. (2010) Common variants in the calcium-sensing receptor gene are associated with total serum calcium levels. *Human Molecular Genetics* 19: 4296–4303.
5. Kapur K, Johnson T, Beckmann ND, Sehmi J, Tanaka T, et al. (2010) Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene. *PLoS Genet* 6: e1001035.
6. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* 44: 491–501.
7. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* 376: 180–188.
8. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, et al. (2009) Mouse GLUT9: evidences for a urate uniporter. *Am J Physiol Renal Physiol* 297: F612–619.
9. Zuber AM, Centeno G, Pradervand S, Nikolaeva S, Maquelin L, et al. (2009) Molecular clock is involved in predictive circadian adjustment of renal function. *Proc Natl Acad Sci U S A* 106: 16523–16528.
10. Peacock M (2010) Calcium metabolism in health and disease. *Clinical journal of the American Society of Nephrology : CJASN* 5 Suppl 1: S23–30.
11. Shu L, Ji J, Zhu Q, Cao G, Karaplis A, et al. (2011) The calcium-sensing receptor mediates bone turnover induced by dietary calcium and parathyroid hormone in neonates. *J Bone Miner Res* 26: 1057–1071.
12. Cheval L, Pierrat F, Dossat C, Genete M, Imbert-Teboul M, et al. (2011) Atlas of gene expression in the mouse kidney: new features of glomerular parietal cells. *Physiol Genomics* 43: 161–173.
13. Chabardes-Garonne D, Mejean A, Aude JC, Cheval L, Di Stefano A, et al. (2003) A panoramic view of gene expression in the human kidney. *Proc Natl Acad Sci U S A* 100: 13710–13715.
14. Murakami T, Sakane F, Imai S, Houkin K, Kanoh H (2003) Identification and characterization of two splice variants of human diacylglycerol kinase eta. *J Biol Chem* 278: 34364–34372.
15. Shulga YV, Topham MK, Epan RM (2011) Regulation and functions of diacylglycerol kinases. *Chem Rev* 111: 6186–6208.
16. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics* 26: 2190–2191.
17. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nature genetics* 44: 491–501.
18. Kestenbaum B, Glazer NL, Kottgen A, Felix JF, Hwang SJ, et al. (2010) Common genetic variants associate with serum phosphorus concentration. *J Am Soc Nephrol* 21: 1223–1232.
19. Wang K, Li M, Hadley D, Liu R, Glessner J, et al. (2007) PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome research* 17: 1665–1674.
20. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, et al. (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. *Diabetes* 57: 3112–3121.
21. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, et al. (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. *Human molecular genetics* 18: 4081–4088.
22. Franceschini N, van Rooij FJ, Prins BP, Feitosa MF, Karakas M, et al. (2012) Discovery and Fine Mapping of Serum Protein Loci through Transethnic Meta-analysis. *American journal of human genetics* 91: 744–753.
23. Zuber AM, Centeno G, Pradervand S, Nikolaeva S, Maquelin L, et al. (2009) Molecular clock is involved in predictive circadian adjustment of renal function. *Proceedings of the National Academy of Sciences of the United States of America* 106: 16523–16528.
24. Sakane F, Imai S, Yamada K, Murakami T, Tsushima S, et al. (2002) Alternative splicing of the human diacylglycerol kinase delta gene generates two isoforms differing in their expression patterns and in regulatory functions. *J Biol Chem* 277: 43519–43526.
25. Okada Y, Imendra KG, Miyazaki T, Hotokezaka H, Fujiyama R, et al. (2011) High extracellular Ca²⁺ stimulates Ca²⁺-activated Cl⁻ currents in frog parathyroid cells through the mediation of arachidonic acid cascade. *PLoS One* 6: e19158.
26. Zheng H, Liu J, Liu C, Lu F, Zhao Y, et al. (2011) Calcium-sensing receptor activating phosphorylation of PKCdelta translocation on mitochondria to induce cardiomyocyte apoptosis during ischemia/reperfusion. *Mol Cell Biochem* 358: 335–343.
27. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, et al. (2012) Landscape of transcription in human cells. *Nature* 489: 101–108.
28. Hosoya T, Maillard I, Engel JD (2010) From the cradle to the grave: activities of GATA-3 throughout T-cell development and differentiation. *Immunol Rev* 238: 110–125.
29. Grote D, Souabni A, Busslinger M, Bouchard M (2006) Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. *Development* 133: 53–61.
30. Haugas M, Lillevali K, Salminen M (2012) Defects in sensory organ morphogenesis and generation of cochlear hair cells in Gata3-deficient mouse embryos. *Hear Res* 283: 151–161.
31. Grigorieva IV, Thakker RV (2011) Transcription factors in parathyroid development: lessons from hypoparathyroid disorders. *Ann N Y Acad Sci* 1237: 24–38.
32. Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, et al. (2000) GATA3 haplo-insufficiency causes human HDR syndrome. *Nature* 406: 419–422.
33. Bilous RW, Murty G, Parkinson DB, Thakker RV, Coulthard MG, et al. (1992) Brief report: autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia. *N Engl J Med* 327: 1069–1074.
34. Lakshmanan G, Lieuw KH, Lim KC, Gu Y, Grosveld F, et al. (1999) Localization of distant urogenital system-, central nervous system-, and endocardium-specific transcriptional regulatory elements in the GATA-3 locus. *Mol Cell Biol* 19: 1558–1568.
35. Khandekar M, Suzuki N, Lewton J, Yamamoto M, Engel JD (2004) Multiple, distant Gata2 enhancers specify temporally and tissue-specific patterning in the developing urogenital system. *Mol Cell Biol* 24: 10263–10276.
36. Kourou-Mehr H, Slorach EM, Sternlicht MD, Werb Z (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. *Cell* 127: 1041–1055.
37. Li S, Li J, Tian J, Dong R, Wei J, et al. (2012) Characterization, tissue expression, and imprinting analysis of the porcine CDKN1C and NAP1L4 genes. *J Biomed Biotechnol* 2012: 946527.
38. Okada M, Hozumi Y, Ichimura T, Tanaka T, Hasegawa H, et al. (2011) Interaction of nucleosome assembly proteins abolishes nuclear localization of DGKzeta by attenuating its association with importins. *Exp Cell Res* 317: 2853–2863.
39. Xiao H, Shan L, Zhu H, Xue F (2012) Detection of significant pathways in osteoporosis based on graph clustering. *Mol Med Report* 6: 1325–1332.
40. Lim AL, Ng S, Leow SC, Choo R, Ito M, et al. (2012) Epigenetic state and expression of imprinted genes in umbilical cord correlates with growth parameters in human pregnancy. *J Med Genet*.
41. Apostolidou S, Abu-Amero S, O'Donoghue K, Frost J, Olafsdottir O, et al. (2007) Elevated placental expression of the imprinted PHLDA2 gene is associated with low birth weight. *J Mol Med (Berl)* 85: 379–387.
42. Ishida M, Monk D, Duncan AJ, Abu-Amero S, Chong J, et al. (2012) Maternal inheritance of a promoter variant in the imprinted PHLDA2 gene significantly increases birth weight. *Am J Hum Genet* 90: 715–719.
43. Lewis RM, Cleal JK, Ntani G, Crozier SR, Mahon PA, et al. (2012) Relationship between placental expression of the imprinted PHLDA2 gene, intrauterine skeletal growth and childhood bone mass. *Bone* 50: 337–342.
44. Huang J, Wang L, Jiang M, Lin H, Qi L, et al. (2012) PTHLH coupling upstream negative regulation of fatty acid biosynthesis and Wnt receptor signal to downstream peptidase activity-induced apoptosis network in human hepatocellular carcinoma by systems-theoretical analysis. *J Recept Signal Transduct Res* 32: 250–256.
45. Miralibakari BA, Asa SL, Boudreau SF (1992) Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. *Hum Pathol* 23: 884–887.
46. VanHouten J, Dann P, McGeoch G, Brown EM, Krapcho K, et al. (2004) The calcium-sensing receptor regulates mammary gland parathyroid hormone-related protein production and calcium transport. *J Clin Invest* 113: 598–608.
47. Li Y, Meng G, Guo QN (2008) Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. *Exp Mol Pathol* 84: 234–239.
48. Arboleda VA, Lee H, Parnaik R, Fleming A, Banerjee A, et al. (2012) Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. *Nat Genet* 44: 788–792.
49. Zierold C, Reinholz GG, Mings JA, Pahl JM, DeLuca HF (2000) Regulation of the procine 1,25-dihydroxyvitamin D₃-24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D₃ and parathyroid hormone in AOK-B50 cells. *Arch Biochem Biophys* 381: 323–327.
50. Shinki T, Jin CH, Nishimura A, Nagai Y, Ohya Y, et al. (1992) Parathyroid hormone inhibits 25-hydroxyvitamin D₃-24-hydroxylase mRNA expression stimulated by 1 alpha,25-dihydroxyvitamin D₃ in rat kidney but not in intestine. *J Biol Chem* 267: 13757–13762.
51. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res* 19: 429–435.
52. Wöhrle S, Bonny O, Beluch N, Gaulis S, Stamm C, et al. (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. *J Bone Miner Res* 26: 2486–2497.
53. Perwad F, Zhang MY, Tenenhouse HS, Portale AA (2007) Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. *Am J Physiol Renal Physiol* 293: F1577–F1583.